tovorafenib - Profile

What are the generic sources for tovorafenib and what is the scope of patent protection?

Tovorafenib is the generic ingredient in one branded drug marketed by Day One Biopharms and is included in two NDAs. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Tovorafenib has fifty patent family members in twenty-seven countries.

Summary for tovorafenib

International Patents:	50
US Patents:	2
Tradenames:	1
Applicants:	1
NDAs:	2

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for tovorafenib

Constraining patent/regulatory exclusivity:

TREATMENT OF PATIENTS 6 MONTHS OF AGE AND OLDER WITH RELAPSED OR REFRACTORY PEDIATRIC LOW-GRADE GLIOMA (LGG) HARBORING A BRAF FUSION OR REARRANGEMENT, OR BRAF V600 MUTATION

Dosage:

FOR SUSPENSION;ORAL

Constraining patent/regulatory exclusivity:

TREATMENT OF PATIENTS 6 MONTHS OF AGE AND OLDER WITH RELAPSED OR REFRACTORY PEDIATRIC LOW-GRADE GLIOMA (LGG) HARBORING A BRAF FUSION OR REARRANGEMENT, OR BRAF V600 MUTATION

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for tovorafenib

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Day One Biopharms	OJEMDA	tovorafenib	FOR SUSPENSION;ORAL	218033-001	Apr 23, 2024		RX	Yes	Yes	8,293,752		Y	Y
Day One Biopharms	OJEMDA	tovorafenib	FOR SUSPENSION;ORAL	218033-001	Apr 23, 2024		RX	Yes	Yes	10,426,782		Y
Day One Biopharms	OJEMDA	tovorafenib	FOR SUSPENSION;ORAL	218033-001	Apr 23, 2024		RX	Yes	Yes
Day One Biopharms	OJEMDA	tovorafenib	FOR SUSPENSION;ORAL	218033-001	Apr 23, 2024		RX	Yes	Yes
Day One Biopharms	OJEMDA	tovorafenib	TABLET;ORAL	217700-001	Apr 23, 2024		RX	Yes	Yes	10,426,782		Y
Day One Biopharms	OJEMDA	tovorafenib	TABLET;ORAL	217700-001	Apr 23, 2024		RX	Yes	Yes	8,293,752		Y	Y

International Patents for tovorafenib

Country	Patent Number	Title	Estimated Expiration
Taiwan	200916467	Compounds useful as Raf kinase inhibitors
World Intellectual Property Organization (WIPO)	2009006389
Spain	2635729
Russian Federation	2492166	СОЕДИНЕНИЯ, ПОДХОДЯЩИЕ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ RAF (COMPOUNDS SUITABLE FOR USE AS RAF KINASE INHIBITORS)
Japan	6571105
European Patent Office	3122334

Tovorafenib: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

---

Summary

Tovorafenib is an investigational, selective RAF kinase inhibitor primarily targeting cancers driven by BRAF mutations. While still in the clinical trial phase, its potential to address a niche yet significant segment of oncology offers substantial investment and market opportunities. This analysis explores the current developmental status, anticipated market landscape, financial outlook, competitive environment, and strategic considerations for stakeholders interested in tovorafenib's commercialization.

---

1. Development Status and Clinical Pipeline Overview

Parameter	Details
Developer	CStone Pharmaceuticals (collaborations with others)
Indication	Primarily pediatric low-grade gliomas and BRAF-mutant tumors
Phase	Phase 2 (as of 2023); ongoing early-stage trials for multiple indications
Regulatory Status	Pending FDA and EMA feedback; no marketing approval as of Q1 2023

Key Points:

• Tovorafenib has demonstrated promising preliminary efficacy in early trials, particularly in pediatric low-grade gliomas, a niche with high unmet medical needs.
• The compound's selectivity for mutant BRAF sets it apart from multi-kinase inhibitors, potentially reducing off-target effects.

2. Market Dynamics and Competitive Landscape

2.1. Oncology Market Focus

• Low-grade Gliomas (LGGs): Estimated global pediatric brain tumor incidence of ~4.6 per 100,000, with BRAF mutations present in up to 60%-80% of cases (Source: WHO and published studies).
• BRAF-Mutant Cancers: Includes melanoma, lung, colorectal, and other solid tumors — expanding potential indications.

2.2. Key Market Players

Company	Product/Compound	Status	Market Share	Notes
Array BioPharma / Pfizer	Vemurafenib, Dabrafenib	Approved	High in melanoma	First-generation BRAF inhibitors
Novartis	Lumakras (KRAS G12C inhibitor)	Approved	Targeting related pathways	Competitive with BRAF-targeted therapies
CStone Pharmaceuticals	Tovorafenib	Phase 2	Pending	Differentiation via selectivity and pediatric focus

2.3. Key Market Drivers

• Increasing incidence of BRAF mutations across multiple tumor types.
• Growing inclusion of molecular testing in standard oncology protocols.
• Unmet needs in pediatric brain tumors, especially with limited treatment options.

2.4. Challenges

• Stringent regulatory requirements for pediatric indications.
• Competition from existing BRAF inhibitors with established efficacy.
• Need for combination therapies to enhance response rates.

---

3. Financial Trajectory and Investment Outlook

Aspect	Details
Development Costs	Estimated at $50-100 million for late-stage trials, considering clinical trial phases and regulatory submissions.
Market Entry Timing	Anticipated FDA approval window: 2025–2026, based on trial results and regulatory review timelines.
Pricing Potential	Pediatric brain tumor therapies in the US can command premium prices (~$150,000–$250,000 annually).
Revenue Projections	For initial indications, conservative estimates project peak annual revenues of $500 million–$1 billion, assuming approval for broader indications.

Financial Model Assumptions:

• Successful Phase 2 data leading to accelerated approval pathways.
• Market penetration of approximately 20–30% in initial indications.
• Price points aligned with existing targeted therapies.

Projected Financial Milestones	2023	2024	2025	2026
Trial Completion & Data Readout	Ongoing	Data readout	Data readout	N/A
Regulatory Submission	N/A	2024	2025	N/A
Potential Approval & Commercialization	N/A	N/A	2025–2026	2026+

4. Risk Analysis and Strategic Considerations

Risk Factor	Implication	Mitigation Strategies
Clinical Trial Failures	Delays or termination	Diversify indications; early biomarker validation
Regulatory Hurdles	Approval delays	Engage early with regulators; adaptive trial designs
Market Adoption	Slower uptake	Competitive differentiation; partnering for reimbursement strategies
Competitive Pressure	Loss of market share	Focus on pediatric niche; combination approaches

---

5. Comparative Analysis with Similar Compounds

Parameter	Tovorafenib	Vemurafenib (Zelboraf)	Dabrafenib (Tafinlar)
Target	Selective BRAF inhibitor	BRAF V600E mutation	BRAF V600E mutation
Approved Indications	Pending pediatric gliomas, other solid tumors	Melanoma, NSCLC	Melanoma, thyroid carcinoma
Pricing (US)	Estimated $150,000–$200,000/year	~$125,000/year	~$125,000/year
Market Penetration	Potential first in pediatric low-grade gliomas	Established	Established

---

6. Regulatory and Policy Landscape

• Orphan Drug Designation: Possible for pediatric indications, offering benefits like market exclusivity and fee reductions.
• Fast Track/Breakthrough Status: Potential pathways for accelerated approval based on preliminary efficacy data.

---

Key Takeaways

• Tovorafenib positions as a high-potential, targeted oncology therapy with particular appeal in pediatric low-grade gliomas.

• Market adoption depends heavily on positive trial results, regulatory approvals (anticipated 2025–2026), and successful commercialization strategies targeting pediatric oncology and broader BRAF-mutant tumors.

• Competitive landscape is consolidating, but the differentiation via selectivity and pediatric focus could offer strategic advantages.

• Investment in tovofarenib demands careful risk management, including clinical, regulatory, and market acceptance considerations.

---

FAQs

Q1. What are the primary indications being targeted for tovofarenib?
A: Pediatric low-grade gliomas and other BRAF-mutant solid tumors. Clinical trials are expanding to include adult tumors with BRAF mutations.

Q2. How does tovofarenib compare to existing BRAF inhibitors?
A: It is more selective, potentially reducing off-target effects. Its primary advantage is expected in pediatric patients and in combination strategies requiring fewer side effects.

Q3. When is tovofarenib expected to gain regulatory approval?
A: Based on current trial progress, anticipated between 2025 and 2026, contingent on successful trial outcomes.

Q4. What are the main market entry barriers?
A: Regulatory hurdles, especially for pediatric indications, competition with established therapies, and the need for robust clinical evidence.

Q5. What is the potential revenue outlook for tovofarenib?
A: Peak annual revenues could reach $500 million to $1 billion across multiple indications, assuming successful approval and market penetration.

---

References

[1] World Health Organization. (2021). Incidence of pediatric brain tumors.
[2] ClinicalTrials.gov. (2023). Tovorafenib Trials.
[3] MarketWatch. (2023). Oncology targeted therapy prices and trends.
[4] Novartis Annual Report 2022.
[5] U.S. FDA. Orphan Drug Designation Policies, 2022.